Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Neurocrine Biosciences (NBIX) stocks in Canada
Learn how to easily invest in Neurocrine Biosciences stocks.
Neurocrine Biosciences is a drug manufacturers-specialty & generic business based in the US. Neurocrine Biosciences stocks (NBIX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $98.99 – an increase of 2.97% over the previous week. Neurocrine Biosciences employs 1,200 staff and has a trailing 12-month revenue of around $1.5 billion.
How to buy Neurocrine Biosciences stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – NBIX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
CIBC Investor's Edge
- Easy to use platform
- Low fees
- Student and young investor discounts
- Access to international stock exchanges
- Low margin rates
- Powerful research tools
National Bank Direct Brokerage
- Commission-free trading
- Several account types available
- Access to array of research tools
What's in this guide?
- Can I buy shares in Neurocrine Biosciences?
- Has coronavirus impacted Neurocrine Biosciences shares?
- Neurocrine Biosciences shares summary
- Compare share dealing platforms
- Is Neurocrine Biosciences stock a buy or sell?
- Neurocrine Biosciences performance over time
- Are Neurocrine Biosciences shares over-valued?
- Neurocrine Biosciences's financials
- How volatile are Neurocrine Biosciences shares?
- Does Neurocrine Biosciences pay a dividend?
- Other common questions
Neurocrine Biosciences stock price (NASDAQ:NBIX)Use our graph to track the performance of NBIX stocks over time.
Neurocrine Biosciences shares at a glance
|Latest market close||$97.05|
|52-week range||$75.25 - $129.29|
|50-day moving average||$103.46|
|200-day moving average||$106.77|
|Wall St. target price||$126.22|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$1.60|
Buy Neurocrine Biosciences stocks from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Neurocrine Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Neurocrine Biosciences price performance over time
Historical closes compared with the close of $97.05 from 2023-03-24
|1 week (2023-03-17)||2.97%|
|1 month (2023-02-24)||-5.27%|
|3 months (2022-12-23)||-19.33%|
|6 months (2022-09-26)||-3.50%|
|1 year (2022-03-22)||N/A|
|2 years (2021-03-26)||-1.83%|
|3 years (2020-03-26)||4.90%|
|5 years (2018-03-23)||19.08%|
Is Neurocrine Biosciences stock undervalued or overvalued?
Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Neurocrine Biosciences's P/E ratio
Neurocrine Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, Neurocrine Biosciences shares trade at around 59x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Neurocrine Biosciences's PEG ratio
Neurocrine Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.87. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Neurocrine Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Neurocrine Biosciences's EBITDA
Neurocrine Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $264.1 million.
The EBITDA is a measure of a Neurocrine Biosciences's overall financial performance and is widely used to measure a its profitability.
Neurocrine Biosciences financials
|Revenue TTM||$1.5 billion|
|Operating margin TTM||16.73%|
|Gross profit TTM||$1 billion|
|Return on assets TTM||7.01%|
|Return on equity TTM||10.03%|
|Market capitalisation||$9.2 billion|
TTM: trailing 12 months
Neurocrine Biosciences share dividends
We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.
Neurocrine Biosciences share price volatility
Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $75.25 up to $129.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 0.4974. This would suggest that Neurocrine Biosciences's shares are less volatile than average (for this exchange).
Neurocrine Biosciences overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia.
Neurocrine Biosciences in the news
Neurocrine Biosciences to Present at the Stifel 2023 CNS Days
3 Growth Stocks That Could Disrupt the Healthcare Industry
Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
How do ETFs work?
Your guide to how ETFs work and whether this type of investment is right for you.Read more…
Best stock app for beginners
The best stock trading app for beginners is easy to use and offers free trades.Read more…
How to read stock charts
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.Read more…
More guides on Finder
How to buy Neuraxis (NRXS) stock in Canada when it goes public
Everything we know about the Neuraxis IPO plus information on how to buy in.
How to buy Brera (BREA) stock in Canada
Everything we know about the Brera IPO plus information on how to buy in.
How to buy TXO Energy (TXO) stock in Canada
Everything we know about the TXO Energy IPO plus information on how to buy in.
How do ETFs work?
Your guide to how ETFs work and whether this type of investment is right for you.
How to buy Torex Gold stock in Canada
Steps to owning and managing TXG stock, with 24-hour and historical pricing before you buy.
Best stock app for beginners
The best stock trading app for beginners is easy to use and offers free trades.
How to read stock charts
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
3 upcoming IPOs to watch in March 2023
An healthcare company, NFT tech developer and baby products retailer are among the IPOs expected to take place this month.
What are stocks?
Owning a stock means you own part of a company and can potentially grow your wealth. But there is a risk of loss.
Best time to buy stocks
The best time to buy stocks could be right after an IPO, during expansion periods or when other investors are buying or selling.
Ask an Expert
You must be logged in to post a comment.